Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

2.

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Breast Cancer Res Treat. 2012 Jan;131(1):295-306. doi: 10.1007/s10549-011-1741-6. Epub 2011 Sep 4.

3.

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.

BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS.

N Engl J Med. 2009 Aug 20;361(8):766-76. doi: 10.1056/NEJMoa0810818.

4.

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group.

Clin Trials. 2009 Jun;6(3):272-87. doi: 10.1177/1740774509105380.

5.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.

Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, Thürlimann B, Mouridsen H, Campone M, Forbes JF, Paridaens RJ, Colleoni M, Pienkowski T, Nogaret JM, Láng I, Smith I, Gelber RD, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Ann Oncol. 2009 Sep;20(9):1489-98. doi: 10.1093/annonc/mdp033. Epub 2009 May 27.

6.

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole.

Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, Neven P, Orosz Z, Olszewski WP, Knox F, Thürlimann B, Price KN, Castiglione-Gertsch M, Gelber RD, Gusterson BA, Goldhirsch A; Breast International Group Trial 1-98.

J Clin Oncol. 2008 Dec 1;26(34):5569-75. doi: 10.1200/JCO.2008.17.0829. Epub 2008 Nov 3.

7.

[Consensus Document. Update on latex exposure and use of gloves in Italian health care settings].

Crippa M, Balbiani L, Baruffini A, Belleri L, Draicchio F, Feltrin G, Larese F, Maggio GM, Marcer G, Micheloni GP, Montomoli L, Moscato G, Previdi M, Sartorelli P, Sossai D, Spatari G, Zanetti C.

Med Lav. 2008 Sep-Oct;99(5):387-99. Italian.

PMID:
18828538
8.

[Latex and synthetic polymers gloves: protective effectiveness against biological risk].

Balbiani L, Sossai D.

Med Lav. 2008 Mar-Apr;99(2):102-7. Review. Italian.

PMID:
18510272
9.

[Individual protection devices: anti-vibration gloves].

Balbiani L.

G Ital Med Lav Ergon. 2004 Apr-Jun;26(2):140-2. Italian. No abstract available.

PMID:
15270444
10.

[Cardiopathy caused by physical or chemical agents].

Crippa M, Balbiani L.

Med Lav. 2004 Mar-Apr;95(2):110-8. Review. Italian.

PMID:
15218742
11.

Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.

Delfino C, Caccia G, Gonzáles LR, Mickiewicz E, Rodger J, Balbiani L, Morales DF, Comba AZ, Brosio C.

Oncology. 2004;66(1):18-23.

PMID:
15031594
12.

Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.

Delfino C, Caccia G, Riva Gonzáles L, Mickiewicz E, Rodger J, Balbiani L, Flores Morales D, Zori Comba A, Brosio C.

Oncology (Williston Park). 2003 Dec;17(12 Suppl 14):22-5.

PMID:
14768401
13.

[Transcutaneous absorption of industrial toxic substances].

Balbiani L.

G Ital Med Lav Ergon. 2003 Apr-Jun;25(2):182-5. Italian.

PMID:
12872505
14.

Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.

Marantz A, Jovtis S, Almira E, Balbiani L, Castilla JL, Fein L, Lewi D, Pasccon G, Pinckevicius R, Uranga G, Abal M, Muiño M, Reale M, Agusto S; Grupo de Tumores Gastrointestinales.

Semin Oncol. 2001 Jun;28(3 Suppl 10):44-9.

PMID:
11510033
15.

A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.

Zori Comba A, Blajman C, Richardet E, Bella S, Vilanova M, Cóppola F, Van Kooten M, Rodger J, Giglio R, Balbiani L, Perazzo F, Montiel M, Chacón M, Pujol F, Mickiewicz E, Cazap E, Recondo G, Lastiri F, Simon J, Wasserman E, Schmilovich A.

Eur J Cancer. 2001 May;37(8):1006-13.

PMID:
11334726
16.

Phase II of doxorubicin/taxol in metastatic breast cancer. Argentine Multicenter Taxol Group.

Pazos C, Mickiewicz E, Di Notto MR, Cóppola F, Ventriglia M, Jovtis S, Balbiani L, Lewi D, Róndinón M, Témperley G, Trigo M, Bertoncín AM, Pascual M, Uranga G, Cazap E, Breier S, Grasso S, Estévez R, Triguboff E, Alvarez A, Suárez A.

Breast Cancer Res Treat. 1999 May;55(1):91-6.

PMID:
10472783
17.

A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma.

Blajman C, Balbiani L, Block J, Coppola F, Chacon R, Fein L, Bonicatto S, Alvarez A, Schmilovich A, Delgado FM.

Cancer. 1999 Mar 1;85(5):1091-7.

PMID:
10091793
18.

Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study.

Brocato N, Bruno MF, Araujo CE, Cervellino JC, Pirisi C, Temperley G, Sparrow C, Savulsky C, Balbiani LR.

Oncology. 1995 Jan-Feb;52(1):24-31.

PMID:
7800338

Supplemental Content

Loading ...
Support Center